Upper Jaw Mucormycosis in an Immunocompetent Patient: A Clinical Report.

Mucormycosis is a rare but severe opportunistic infection, whose incidence has substantially increased since the coronavirus disease 2019 (COVID-19) pandemic. It predominantly affects immunocompromised patients, individuals with diabetes, and those receiving corticosteroids. Standard treatment involves extensive debridement of affected tissue combined with prolonged antifungal therapy. We present a case of an immunocompetent patient with no identifiable risk factors who developed maxillary mucormycosis associated with COVID-19 illness. The condition responded favorably to minimal debridement and antifungal treatment. This case raises questions about the need for extensive debridement in immunocompetent patients without underlying risk factors.